l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor–α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial

• Published in: Nutrition research (New York, N.Y.) N.Y.), 2018-01, Vol.49, p.96-106
• Main Authors: Houjeghani, Shiva, Kheirouri, Sorayya, Faraji, Esmaeil, Jafarabadi, Mohammad Asghari
• Format: Article
• Language: English
• Subjects: Age; Glycemic status; Inflammation; l-Carnosine; Lipid profile; Type 2 diabetes mellitus
• ISSN: 0271-5317; 1879-0739
• DOI: 10.1016/j.nutres.2017.11.003

Considering the pathologic importance of metabolic disturbances, advanced glycation end products (AGEs), and chronic inflammation in diabetes mellitus and ameliorating potentials of l-carnosine in hampering these detritions and because these effects have not been investigated in patients with type 2 diabetes (T2D) so far, we conducted the current study. We hypothesized that l-carnosine would improve glycemic control, lipid profile, AGE, soluble receptor of AGEs (sRAGE), and inflammatory markers. In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n=27, receiving 2 capsules of l-carnosine 500 mg each) or control group (n=27). Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention. l-Carnosine supplementation resulted in significant decrease in fat mass and an increase in fat-free mass in the intervention group compared with the placebo group (1.5% and 1.7%, respectively) (P